NorthWest Biotherapeutics Inc (NWBO)

[VuBru]

AVI - Interesting idea. So you think the paper could report even a failure of PFS as primary, but then slip in positive info on the long tail OS results? The company's statements seem to suggest that they are excited about the results presented in the paper, and certainly reporting failed PFS would not be exciting to them. Is there a precedent for this type of mixed blinded/unblinded publication? If you are correct, this could certainly help them get this manuscript describing blinded long-term survival findings (their top focus now) into a top quality journal.

Regarding the number of authors, who cares. Whether 5 or 65 is not going to really matter. I don't think anyone judges the value of science by the number of authors associated with it. The only thing I take from the company's "number of authors" comment is that they had a lot of administrative hassles in getting this manuscript done.